These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25504164)

  • 21. Cardiovascular disease in chronic kidney disease: risk factors, pathogenesis, and prevention.
    Ardhanari S; Alpert MA; Aggarwal K
    Adv Perit Dial; 2014; 30():40-53. PubMed ID: 25338421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy.
    Wang X; Liu J; Drummond CA; Shapiro JI
    Expert Opin Ther Targets; 2017 May; 21(5):531-541. PubMed ID: 28338377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients.
    Liabeuf S; Lenglet A; Desjardins L; Neirynck N; Glorieux G; Lemke HD; Vanholder R; Diouf M; Choukroun G; Massy ZA;
    Kidney Int; 2012 Dec; 82(12):1297-303. PubMed ID: 22895515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac Magnetic Resonance Imaging of the Myocardium in Chronic Kidney Disease.
    Kis E; Ablonczy L; Reusz GS
    Kidney Blood Press Res; 2018; 43(1):134-142. PubMed ID: 29444516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac metabolic remodelling in chronic kidney disease.
    Patel N; Yaqoob MM; Aksentijevic D
    Nat Rev Nephrol; 2022 Aug; 18(8):524-537. PubMed ID: 35637381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Echocardiography to predict adverse cardiac and vascular events in patients with severe chronic kidney disease (stage 4): a prospective study.
    Lesaffre F; Wynckel A; Nazeyrollas P; Rieu P; Metz D
    Arch Cardiovasc Dis; 2013 Apr; 106(4):220-7. PubMed ID: 23706368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Left ventricular remodeling and arterial remodeling in patients with chronic kidney disease stage 1-3.
    Pluta A; Stróżecki P; Krintus M; Odrowąż-Sypniewska G; Manitius J
    Ren Fail; 2015 Aug; 37(7):1105-10. PubMed ID: 26156686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A look at the upper heart chamber: the left atrium in chronic kidney disease.
    Paoletti E; Zoccali C
    Nephrol Dial Transplant; 2014 Oct; 29(10):1847-53. PubMed ID: 24286975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cardioprotection: an essential component for predialysis chronic renal failure treatment].
    Jungers P; Qualim Z; Nguyen-Khoa T; Massy Z; London G
    Nephrologie; 2003; 24(2):79-88. PubMed ID: 12723513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What happens to the heart in chronic kidney disease?
    Rutherford E; Mark PB
    J R Coll Physicians Edinb; 2017 Mar; 47(1):76-82. PubMed ID: 28569289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac Imaging in Chronic Kidney Disease Patients.
    Raggi P; Alexopoulos N
    Semin Dial; 2017 Jul; 30(4):353-360. PubMed ID: 28326604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Potential of Targeting Fibroblast Growth Factor-23 and αKlotho in the Treatment of Uremic Cardiomyopathy.
    Law JP; Price AM; Pickup L; Radhakrishnan A; Weston C; Jones AM; McGettrick HM; Chua W; Steeds RP; Fabritz L; Kirchhof P; Pavlovic D; Townend JN; Ferro CJ
    J Am Heart Assoc; 2020 Apr; 9(7):e016041. PubMed ID: 32212912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Cardiovascular Markers in Chronic Kidney Disease.
    Chen SC; Huang JC; Su HM; Chiu YW; Chang JM; Hwang SJ; Chen HC
    Kidney Blood Press Res; 2018; 43(4):1388-1407. PubMed ID: 30153666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Vascular dysfunction in Cardiorenal Syndrome type 4].
    Sessa C; Granata A; Gaudio A; Xourafa A; Malatino L; Lentini P; Fatuzzo P; Rapisarda F; Castellino P; Zanoli L
    G Ital Nefrol; 2020 Feb; 37(1):. PubMed ID: 32068357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chronic kidney disease-a cardiovascular high-risk constellation].
    Speer T; Schunk SJ; Fliser D
    Internist (Berl); 2020 Apr; 61(4):340-348. PubMed ID: 31578597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulmonary hypertension: epidemiology in different CKD stages and its association with cardiovascular morbidity.
    Li Z; Liang X; Liu S; Ye Z; Chen Y; Wang W; Li R; Xu L; Feng Z; Shi W
    PLoS One; 2014; 9(12):e114392. PubMed ID: 25525807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac imaging in patients with chronic kidney disease.
    Chiu DY; Green D; Abidin N; Sinha S; Kalra PA
    Nat Rev Nephrol; 2015 Apr; 11(4):207-20. PubMed ID: 25561081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations.
    Law JP; Pickup L; Pavlovic D; Townend JN; Ferro CJ
    J Hum Hypertens; 2023 Jan; 37(1):1-19. PubMed ID: 36138105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
    Charytan DM; Lewis EF; Desai AS; Weinrauch LA; Ivanovich P; Toto RD; Claggett B; Liu J; Hartley LH; Finn P; Singh AK; Levey AS; Pfeffer MA; McMurray JJ; Solomon SD
    Am J Kidney Dis; 2015 Sep; 66(3):429-40. PubMed ID: 25935581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging of Myocardial Fibrosis in Patients with End-Stage Renal Disease: Current Limitations and Future Possibilities.
    Graham-Brown MP; Patel AS; Stensel DJ; March DS; Marsh AM; McAdam J; McCann GP; Burton JO
    Biomed Res Int; 2017; 2017():5453606. PubMed ID: 28349062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.